ダブルストロボレンジファインダの開発(特別講演)(画像センシングおよび一般)

    January 2002 in “ 映像情報メディア学会技術報告 ”
    健夫 吾妻, 謹也 魚森
    TLDR Some prostate cancers have gene changes that may affect treatment with certain drugs.
    The study investigated the SRD5A2 gene, which encodes the enzyme steroid 5alpha-reductase, in 30 prostate adenocarcinomas, identifying 17 de novo amino-acid substitutions in 13 tumors and six silent substitutions. Overall, 60% of the tumors had somatic substitutions in the gene's coding region. Biochemical and pharmacological characterization of these missense substitutions showed that two increased enzyme activity, potentially raising DHT levels and contributing to prostate cancer progression. The study highlighted variability in response to 5alpha-reductase inhibitors, such as finasteride, suggesting that these findings should inform prevention and treatment strategies for prostate cancer.
    Discuss this study in the Community →